Drug intelligence / Profile preview

DX-101

Development stage: Preclinical
Lead developer: Delonix Bioworks
Modality: Vaccines & Immunotherapeutics

Overview

DX-101 is a live attenuated bacterial vaccine being developed by Delonix Bioworks for the prevention and treatment of *Staphylococcus aureus* (S. aureus) infections. Developed using the company's proprietary ProBVax platform, DX-101 consists of a genetically engineered, weakened bacterial strain designed to trigger a robust and broad-spectrum immune response against S. aureus. The vaccine aims to address the significant global health challenge posed by S. aureus, including antibiotic-resistant strains like MRSA. As of 2024, DX-101 is in the IND-enabling phase, representing the most advanced program in the Delonix Bioworks pipeline.

Beyond the preview

Go deeper on DX-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DX-101.

Explore the full profile